Loading
ACNS1422 tests whether children with the WNT type of medulloblastoma, who almost always survive, can be given less radiotherapy to the brain and spine and less chemotherapy without more relapses; it has finished enrolling and the results are awaited.
ACNS1422 is a single-arm Children's Oncology Group phase 2 study of reduced therapy for children with average-risk WNT-activated medulloblastoma, a subgroup with survival above 90 percent on standard treatment. Craniospinal irradiation is reduced from 23.4 Gy to 18 Gy with a reduced boost volume, and maintenance chemotherapy is shortened. The primary endpoint is progression-free survival.
The registry gives an estimated enrolment of 45 with a primary completion date of March 2028 and no results. The corpus's WNT medulloblastoma page cites it with the St. Jude SJMB12 study (15 Gy) as the trials that define reduced-dose radiotherapy for this subgroup.
Shares WNT-activated medulloblastoma, Brain and spinal cord tumours (all types), Medulloblastoma, Childhood cancers (all types) and the tag soc-trials.
Shares Brain and spinal cord tumours (all types), Childhood cancers (all types), Children's Oncology Group (COG), Vincristine and the tag soc-trials.
Shares Brain and spinal cord tumours (all types), Childhood cancers (all types), Children's Oncology Group (COG), Vincristine and the tag soc-trials.
Shares Childhood cancers (all types), Vincristine, Cyclophosphamide, IMRT / IGRT (modern external beam) and the tag soc-trials.
Shares Childhood cancers (all types), Children's Oncology Group (COG), Vincristine, Cyclophosphamide and the tag soc-trials.
Shares Brain and spinal cord tumours (all types), Childhood cancers (all types), Children's Oncology Group (COG), IMRT / IGRT (modern external beam) and the tag soc-trials.
Shares Childhood cancers (all types), Children's Oncology Group (COG), Vincristine, Cyclophosphamide and the tag soc-trials.
Shares Childhood cancers (all types), Children's Oncology Group (COG), Vincristine, Cyclophosphamide and the tag soc-trials.